Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

 
• By Ian Haydock, Jung Won Shin, Brian Yang, and Joseph Haas

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

IgA Glomerulonephritis Illustration
IgA nephropathy is far more prevalent in China than in the US or Europe

More from Strategy

More from Business